Co-Diagnostics, Inc. To Host Booth At Medlab Africa 2023 In Johannesburg
Co-Diagnostics, Inc. To Host Booth At Medlab Africa 2023 In Johannesburg. Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that the company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 17-19, 2023.
The conference is described as the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of professionals from the South African Development Community region and around the world, including distributors, government representatives, laboratory executives, and purchasing/procurement managers, who attend to meet with world-class suppliers and manufacturers.
Co-Dx believes that the trade show will contribute valuable insight into markets that are anticipated to play an important role in the Company’s future as it prepares to launch its upcoming Co-Dx PCR Home™ platform. In addition to a test for COVID-19, which is currently undergoing clinical evaluations on the platform in preparation for a submission to the FDA, Co-Dx has several other infectious disease tests in varying stages of development. One of these tests is for tuberculosis (TB), a disease for which the World Health Organization estimates 25% of new cases and deaths globally are found in the African region. Nigeria and South Africa are two of the 7 countries which have been estimated to account for over two thirds of global TB cases.
Co-Dx recently announced that it had received funding support from the Bill & Melinda Gates Foundation to be used towards completion of the TB test on the new Co-Dx PCR Home platform.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.
